CARL ALLEN to Adult
This is a "connection" page, showing publications CARL ALLEN has written about Adult.
Connection Strength
0.495
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
Score: 0.056
-
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024 05 14; 8(9):2248-2258.
Score: 0.056
-
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018 09 27; 132(13):1438-1451.
Score: 0.037
-
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
Score: 0.037
-
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
Score: 0.033
-
How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
Score: 0.030
-
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis Rheumatol. 2025 Feb; 77(2):226-238.
Score: 0.014
-
Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
Score: 0.014
-
Pediatric HIV+ Kaposi sarcoma exhibits clinical, virological, and molecular features different from the adult disease. JCI Insight. 2023 11 22; 8(22).
Score: 0.014
-
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis Rheumatol. 2023 10; 75(10):1714-1732.
Score: 0.013
-
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023 10; 82(10):1271-1285.
Score: 0.013
-
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 12; 177:120-142.
Score: 0.013
-
Prevalence of the BRAFV600E mutation in Greek adults with Langerhans cell histiocytosis. Pediatr Hematol Oncol. 2022 Sep; 39(6):540-548.
Score: 0.012
-
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021 04 29; 137(17):2337-2346.
Score: 0.011
-
Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol. 2021 02; 192(3):667-671.
Score: 0.011
-
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
Score: 0.010
-
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
Score: 0.010
-
The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
Score: 0.009
-
Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
Score: 0.009
-
A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017 Sep 01; 123(17):3229-3240.
Score: 0.009
-
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
Score: 0.009
-
Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.008
-
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.008
-
Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
Score: 0.008
-
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol. 2017 01; 139(1):232-245.
Score: 0.008
-
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66.
Score: 0.008
-
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 06 02; 127(22):2672-81.
Score: 0.008
-
The evolution of cellular deficiency in GATA2 mutation. Blood. 2014 Feb 06; 123(6):863-74.
Score: 0.007
-
Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
Score: 0.006
-
Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
Score: 0.006
-
Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
Score: 0.005
-
Pediatric residency duty hours before and after limitations. Pediatrics. 2006 Dec; 118(6):e1805-11.
Score: 0.004